Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the pricing of its public offering of 3 million shares at $46 each, aiming to raise approximately $138 million. This capital will mainly support the development of its lead drug, DCCR tablets, designed to treat Prader-Willi Syndrome. The offering, expected to close by May 2024, also includes an underwriters’ option for an additional 450,000 shares. Piper Sandler, Guggenheim Securities, Cantor Fitzgerald & Co., Oppenheimer & Co., and Laidlaw & Company are collectively managing the book-running, with the funds raised destined for R&D, possibly extending to acquisitions, though none are specifically planned. The offering leverages a registration statement on Form S-3ASR filed with the SEC and took effect in January 2024, with the prospectus and related filings accessible through the SEC or the book-runners. The announcement also includes information on Soleno’s progress with DCCR, the associated risks, market conditions for the offering’s success, and regulatory compliance statements.

Biopharmaceuticals, Healthcare, Investment Banking and Brokerage Services,United States